Metastatic transitional cell carcinoma is an advanced form of cancer that has spread beyond its original location in the urinary system to distant parts of the body. Treatment focuses on prolonging life, managing symptoms, and maintaining quality of life through a combination of established therapies and emerging approaches currently being tested in clinical trials.

Understanding Treatment Goals for Advanced Disease

When transitional cell carcinoma spreads beyond the kidney, ureter, or bladder to other organs, treatment shifts from attempting to cure the disease to managing it as effectively as possible. The main goals include slowing the growth of cancer, reducing symptoms, improving how you feel day to day, and extending survival. In rare cases, treatment might lead to a cure, though this is uncommon with metastatic disease.^[1][2]

Metastatic transitional cell carcinoma means the cancer has traveled from its starting point in the renal pelvis (the collecting area inside the kidney), ureter (the tube connecting kidney to bladder), or bladder to distant sites. Common places where this cancer spreads include the lymph nodes in the pelvis, lungs, liver, bones, and sometimes the brain, especially after chemotherapy treatment. Soft tissue areas like muscles can also be affected, though this is less common.^[2][3]

Your individual treatment plan will depend on several factors. Doctors consider where the cancer started, how far it has spread, how aggressive the cancer cells appear under the microscope, your overall health, and how well your kidneys are functioning. Because many people with this disease have reduced kidney function, either from the cancer itself or from previous surgery, choosing the right treatment requires careful consideration of what your body can tolerate.^[6][10]

Standard Treatment Approaches

The foundation of treatment for metastatic transitional cell carcinoma has traditionally been chemotherapy, particularly combinations that include a platinum-based drug. The most widely used approach is cisplatin-based chemotherapy, which has been the standard first-line treatment for decades. Cisplatin works by interfering with cancer cell DNA, preventing the cells from dividing and growing. It is often combined with other chemotherapy drugs like gemcitabine, methotrexate, vinblastine, and doxorubicin to create powerful treatment combinations.^[8][11]

One common regimen is gemcitabine combined with cisplatin. Another well-established combination is MVAC, which stands for methotrexate, vinblastine, doxorubicin (also called Adriamycin), and cisplatin. These combinations have shown the ability to shrink tumors and extend survival, with median overall survival around 14 months in patients receiving cisplatin-based treatment.^[13]

However, up to half of patients with metastatic disease are not suitable candidates for cisplatin. This is determined using specific criteria that look at kidney function, hearing loss, heart problems, and overall physical condition. For people who cannot receive cisplatin, doctors may use carboplatin, a related platinum drug that is gentler on the kidneys but generally considered less effective. Carboplatin is often paired with gemcitabine as an alternative option.^[8][13]

The duration of chemotherapy varies depending on how well the treatment is working and how well you tolerate it. Typically, patients receive several cycles of treatment, with each cycle lasting a few weeks. Your doctor will monitor your response through imaging tests and blood work to decide whether to continue, adjust, or stop treatment.^[8]

Chemotherapy causes side effects because it affects not only cancer cells but also healthy, rapidly dividing cells in your body. Common side effects include nausea, vomiting, diarrhea, loss of appetite, mouth sores, hair loss, fatigue, and increased risk of infections due to lowered blood counts. Cisplatin in particular can damage the kidneys and nerves, causing numbness or tingling in the hands and feet, a condition called peripheral neuropathy. It can also affect hearing. Some patients must stop treatment early due to toxicity, as these side effects can become severe.^[2][8]

Maintenance therapy with a drug called avelumab has emerged as an important strategy for people whose cancer has responded to initial chemotherapy. Avelumab is a type of immunotherapy that helps the immune system recognize and attack cancer cells. Clinical trials have shown that continuing with avelumab after completing chemotherapy can improve both overall survival and the time before cancer starts growing again, compared to stopping all treatment after chemotherapy. This approach keeps the cancer controlled for longer periods.^[13]

Immunotherapy for Advanced Disease

Immunotherapy has revolutionized the treatment landscape for metastatic transitional cell carcinoma. These drugs work differently from chemotherapy—instead of directly killing cancer cells, they help your own immune system fight the cancer. The immune system normally has built-in brakes that prevent it from attacking the body’s own tissues. Cancer cells can exploit these brakes to hide from immune attack. Immunotherapy drugs release these brakes, allowing immune cells to recognize and destroy cancer cells.^[13]

The main class of immunotherapy used for this cancer is called immune checkpoint inhibitors. These target proteins on immune cells or cancer cells that act as off-switches for the immune response. The most studied checkpoint is called PD-1/PD-L1. When PD-L1 on cancer cells binds to PD-1 on immune cells, it signals the immune system to stand down. Blocking this interaction reactivates the immune attack.^[13]

Several checkpoint inhibitors are approved for use in metastatic transitional cell carcinoma. These include pembrolizumab, atezolizumab, nivolumab, durvalumab, and avelumab. They can be used as first-line treatment for patients who are not candidates for cisplatin chemotherapy, or as second-line treatment after chemotherapy has stopped working.^[8][13]

The side effects of immunotherapy are different from those of chemotherapy. Because these drugs activate the immune system, they can cause the immune system to attack normal tissues, leading to inflammation in various organs. This might affect the lungs, liver, intestines, hormone-producing glands, skin, or other organs. Symptoms can include rash, diarrhea, fatigue, cough, and changes in hormone levels. While many patients tolerate immunotherapy better than chemotherapy, some side effects can be serious and require prompt medical attention. Your medical team will monitor you carefully and may prescribe medications like corticosteroids to calm down excessive immune activity if needed.^[8]

Treatment in Clinical Trials

Clinical trials are testing new combinations and entirely new types of drugs that may offer better outcomes for people with metastatic transitional cell carcinoma. These studies follow a structured process: Phase I trials test safety and determine the right dose in small groups of patients, Phase II trials evaluate whether the treatment works and continue safety monitoring in larger groups, and Phase III trials compare the new treatment directly against current standard treatments in even larger patient populations to see if it truly represents an improvement.^[8]

One of the most exciting developments comes from recent Phase III trials that have changed how doctors approach first-line treatment. The CheckMate 901 trial tested the combination of nivolumab (an immunotherapy drug) plus standard gemcitabine-cisplatin chemotherapy against chemotherapy alone. Results presented in 2023 showed that adding nivolumab to chemotherapy significantly extended median overall survival, delayed cancer progression, and increased the percentage of patients whose tumors shrank or disappeared. This combination approach takes advantage of the different ways chemotherapy and immunotherapy attack cancer—chemotherapy kills cancer cells directly while immunotherapy activates the immune system, and when used together they may work better than either alone.^[13]

Antibody-drug conjugates represent another major advance in clinical trials. These are sophisticated molecules that combine two components: an antibody that seeks out and binds to a specific protein on cancer cells, and a chemotherapy drug attached to the antibody. Think of it like a guided missile—the antibody guides the weapon directly to cancer cells, delivering a concentrated dose of chemotherapy right where it’s needed while sparing healthy tissues. This targeted approach can be more effective and cause fewer side effects than traditional chemotherapy that circulates throughout the entire body.^[13]

The most advanced antibody-drug conjugate in development is enfortumab vedotin. This drug targets a protein called Nectin-4, which is highly expressed on transitional cell carcinoma cells. In the groundbreaking EV-302/KEYNOTE-A39 trial, the combination of enfortumab vedotin plus pembrolizumab (an immunotherapy) was compared to standard chemotherapy as first-line treatment. The combination showed remarkable results: patients lived significantly longer, their cancer was controlled for longer periods, and more patients experienced tumor shrinkage compared to chemotherapy alone. These results were so impressive that this combination may become a new standard of care for many patients with metastatic disease.^[13]

Another antibody-drug conjugate being studied is sacituzumab govitecan, which targets a different protein called Trop-2. Early clinical trials have shown promising activity in patients whose cancer has progressed after previous treatments.^[13]

For patients whose tumors have specific genetic alterations, targeted therapy with FGFR inhibitors offers a personalized treatment approach. FGFR stands for fibroblast growth factor receptor, a protein on the cell surface that sends growth signals into the cell. In about 15 to 20 percent of patients with metastatic transitional cell carcinoma, the genes for FGFR are altered in ways that cause cells to grow out of control. FGFR inhibitors are drugs that specifically block these abnormal growth signals.^[13]

The most studied FGFR inhibitor is erdafitinib. This oral medication has shown significant benefit in patients with FGFR alterations whose cancer progressed after chemotherapy. In a Phase III trial called THOR, erdafitinib demonstrated significantly longer overall survival compared to chemotherapy in patients who had previously received immunotherapy. The drug works by blocking the FGFR pathway, essentially cutting off a signal that tells cancer cells to grow and divide. Before receiving an FGFR inhibitor, your tumor must be tested for these genetic alterations—usually through a biopsy sample sent for specialized genetic testing.^[13]

Common side effects of FGFR inhibitors include changes in phosphate levels in the blood, dry mouth, nail changes, dry skin, diarrhea, and eye problems. Regular monitoring by your medical team helps manage these effects. Some side effects like eye changes require consultation with an eye specialist.^[13]

Other novel approaches being explored in clinical trials include combinations of different immunotherapy drugs, new targeted therapies against other molecular pathways involved in cancer growth, and strategies to overcome resistance when cancers stop responding to treatment. Some trials are investigating whether giving chemotherapy or immunotherapy before or after surgery might improve outcomes in patients with high-risk localized disease before it becomes metastatic. Neoadjuvant chemotherapy—treatment given before surgery—offers the advantage of using cisplatin-based regimens while patients still have maximal kidney function, before it is reduced by removing the kidney. However, large randomized trials in this specific setting have not yet been published.^[8]

Researchers are also working to identify biomarkers—measurable characteristics of the tumor or your immune system that predict which patients will respond best to which treatments. For example, tumors with high levels of PD-L1 expression may respond better to immunotherapy, though this is not a perfect predictor. Ongoing research aims to refine these predictive tools so that treatment can be tailored more precisely to each individual patient.^[13]

Most common treatment methods

• Platinum-based chemotherapy
  • Cisplatin combined with gemcitabine as a first-line standard treatment
  • MVAC combination (methotrexate, vinblastine, doxorubicin, cisplatin) for eligible patients
  • Carboplatin with gemcitabine for cisplatin-ineligible patients
  • Treatment typically given in cycles lasting several weeks
• Immunotherapy (Checkpoint Inhibitors)
  • Pembrolizumab, atezolizumab, nivolumab, durvalumab, or avelumab targeting PD-1/PD-L1 pathway
  • Used as first-line therapy in cisplatin-ineligible patients
  • Used as second-line therapy after chemotherapy progression
  • Avelumab as maintenance therapy after initial chemotherapy response
• Antibody-Drug Conjugates
  • Enfortumab vedotin targeting Nectin-4 protein on cancer cells
  • Often combined with immunotherapy like pembrolizumab
  • Delivers chemotherapy directly to cancer cells through targeted antibody
  • Tested in Phase III trials with significant improvements in survival
• Targeted Therapy
  • Erdafitinib for tumors with FGFR genetic alterations
  • Requires genetic testing of tumor tissue to identify eligible patients
  • Blocks abnormal growth signals in cancer cells with FGFR mutations
  • Demonstrated survival benefit in Phase III trial for previously treated patients
• Combination Approaches
  • Nivolumab plus gemcitabine-cisplatin chemotherapy as first-line treatment
  • Enfortumab vedotin plus pembrolizumab showing superior results to chemotherapy
  • Combining chemotherapy’s direct cell-killing with immunotherapy’s immune activation

Managing Your Journey with Advanced Cancer

Living with metastatic transitional cell carcinoma requires careful monitoring and supportive care alongside active treatment. Regular imaging tests, blood work, and clinical assessments help your medical team track how well treatment is working and whether adjustments are needed. Because the disease and its treatments can affect multiple body systems, you may work with a team of specialists including medical oncologists, urologists, radiologists, pathologists, and supportive care providers.^[8]

Symptom management is a crucial part of care. Pain, fatigue, urinary symptoms, and treatment side effects can all impact quality of life. Palliative care specialists focus specifically on relieving symptoms and improving comfort, and this type of support can be provided alongside active cancer treatment. It’s not the same as hospice or end-of-life care—rather, it’s an extra layer of support that helps you feel as well as possible throughout your treatment journey.^[8]

Because kidney function is often compromised in patients with upper urinary tract cancers, especially after surgery to remove a kidney or ureter, managing kidney health becomes important. Your doctors will monitor kidney function regularly and may adjust medication doses accordingly. Staying well hydrated, avoiding medications that can damage kidneys, and managing blood pressure are all important aspects of protecting remaining kidney function.^[8]

Nutritional support can help maintain strength during treatment. Chemotherapy and cancer itself can reduce appetite and cause weight loss. Working with a dietitian who specializes in cancer care can help you maintain adequate nutrition even when eating is difficult. Small, frequent meals, nutritional supplements, and strategies to manage nausea can all make a difference.^[8]

Emotional and psychological support is equally important. A diagnosis of metastatic cancer affects not just your body but your mental health, relationships, and outlook on life. Many cancer centers offer counseling, support groups, and other resources to help you cope. Connecting with others who have faced similar challenges can provide comfort and practical advice. Some patients find that maintaining activities they enjoy and spending quality time with loved ones helps them navigate this difficult time.^[3]